Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784377 | 1.00 | FFAR1 (0.55) | FFAR1TRPA1CHRM2CHRM1FFAR4 | |
| SCHEMBL5634910 | 0.91 | FFAR1 (0.54) | FFAR1CHRM2CHRM1FFAR4PPARD | |
| SCHEMBL5634911 | 0.91 | FFAR1 (0.54) | FFAR1CHRM2CHRM1FFAR4PPARD | |
| SCHEMBL5634667 | 0.85 | FFAR1 (0.50) | FFAR1CHRM2CHRM1FFAR4PPARD | |
| SCHEMBL5634669 | 0.85 | FFAR1 (0.50) | FFAR1CHRM2CHRM1FFAR4PPARD | |
| SCHEMBL6784254 | 0.84 | FFAR1 (0.44) | FFAR1TRPA1CHRM2CHRM1FFAR4 | |
| SCHEMBL8977007 | 0.82 | FFAR1 (0.48) | FFAR1CHRM2CHRM1FFAR4PPARD | |
| SCHEMBL8977016 | 0.82 | FFAR1 (0.48) | FFAR1CHRM2CHRM1FFAR4PPARD | |
| SCHEMBL5480906 | 0.81 | FFAR1 (0.50) | FFAR1CHRM2CHRM1FFAR4APP | |
| SCHEMBL5480902 | 0.81 | FFAR1 (0.50) | FFAR1CHRM2CHRM1FFAR4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0888355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034899-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | FFAR1 2321/4885TRPA1 2181/4885CHRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.